| Alzheimer and purinergic signaling: Just a matter of inflammation? S Merighi, TE Poloni, A Terrazzan, E Moretti, S Gessi, D Ferrari Cells 10 (5), 1267, 2021 | 19 | 2021 |
| The molecular networks of microRNAs and their targets in the drug resistance of colon carcinoma F Crudele, N Bianchi, A Astolfi, S Grassilli, F Brugnoli, A Terrazzan, ... Cancers 13 (17), 4355, 2021 | 9 | 2021 |
| Circulating microRNAs suggest networks associated with biological functions in aggressive refractory type 2 celiac disease N Bianchi, L Doneda, L Elli, C Taccioli, V Vaira, A Scricciolo, V Lombardo, ... Biomedicines 10 (6), 1408, 2022 | 3 | 2022 |
| Inhibition of the lncRNA coded within transglutaminase 2 gene impacts several relevant networks in MCF-7 breast cancer cells CM Bergamini, C Vischioni, G Aguiari, C Grandi, A Terrazzan, S Volinia, ... Non-coding RNA 7 (3), 49, 2021 | 3 | 2021 |
| Protein kinase C at the crossroad of mutations, cancer, targeted therapy and immune response A Aquino, N Bianchi, A Terrazzan, O Franzese Biology 12 (8), 1047, 2023 | 2 | 2023 |
| Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways F Crudele, N Bianchi, A Terrazzan, P Ancona, A Frassoldati, P Gasparini, ... Biology 12 (4), 493, 2023 | 2 | 2023 |
| A Multidisciplinary Approach Establishes a Link between Transglutaminase 2 and the Kv10.1 Voltage-Dependent K+ Channel in Breast Cancer R Canella, F Brugnoli, M Gallo, JW Keillor, A Terrazzan, E Ferrari, ... Cancers 15 (1), 178, 2022 | 2 | 2022 |
| Metabolic characterisation of transglutaminase 2 inhibitor effects in breast cancer cell lines M Gallo, E Ferrari, A Terrazzan, F Brugnoli, A Spisni, C Taccioli, G Aguiari, ... The FEBS Journal 290 (22), 5411-5433, 2023 | 1 | 2023 |
| Circular RNAs Could Encode Unique Proteins and Affect Cancer Pathways. Biology 2023, 12, 493 F Crudele, N Bianchi, A Terrazzan, P Ancona, A Frassoldati, P Gasparini, ... | 1 | 2023 |
| Transcriptomics Studies Reveal Functions of Transglutaminase 2 in Breast Cancer Cells Using Membrane Permeable and Impermeable Inhibitors P Ancona, A Trentini, A Terrazzan, S Grassilli, P Navals, EWJ Gates, ... Journal of Molecular Biology 436 (10), 168569, 2024 | | 2024 |
| State‐of‐the‐art in transposable element modulation affected by drugs in malignant prostatic cancer cells A Terrazzan, R Vanini, P Ancona, N Bianchi, C Taccioli, G Aguiari Journal of Cellular Biochemistry, 2024 | | 2024 |
| Inhibition of Type 2 Transglutaminase significantly alters long noncoding RNAs expression in triplenegative breast cancer cell line. P Ancona, A Terrazzan, FP Carbone, G Salvi, C Taccioli, S Volinia, ... Inhibition of Type 2 Transglutaminase significantly alters long noncoding …, 2024 | | 2024 |
| Drug repurposing and transposable elements: a new promising strategy to fight prostate cancer P Ancona, A Terrazzan, N Bianchi, C Orlandi, FPIA Carbone, G Aguiari, ... 20th Annual Meeting of the Bioinformatics Italian Society June 12-14, 2024 …, 2024 | | 2024 |
| Inverse Impact of Cancer Drugs on Circular and Linear RNAs in Breast Cancer Cell Lines A Terrazzan, F Crudele, F Corrà, P Ancona, J Palatini, N Bianchi, ... Non-coding RNA 9 (3), 32, 2023 | | 2023 |
| Circulating microRNAs Suggest Networks Associated with Biological Functions in Aggressive Refractory Type 2 Celiac Disease. Biomedicines 2022, 10, 1408 N Bianchi, L Doneda, L Elli, C Taccioli, V Vaira, A Scricciolo, V Lombardo, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| Prelude therapeutics: Transglutaminase type 2 inhibitors target Kv10. 1 channels in triple negative MDA-MB-231 breast cancer cells N Bianchi, CM Bergamini, A Terrazzan, JW Keillor, R Canella Signal transduction receptors, mediators, and genes, 98-98, 2021 | | 2021 |
